Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2017 from OUS - Department of Gynaecological Oncology
24 publications found
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Oncotarget, 8 (37), 61800-61809
DOI 10.18632/oncotarget.18694, PubMed 28977905
Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
Virchows Arch, 471 (3), 355-362
DOI 10.1007/s00428-017-2172-5, PubMed 28643014
A Comparison of the Detection of Sentinel Lymph Nodes Using Indocyanine Green and Near-Infrared Fluorescence Imaging Versus Blue Dye During Robotic Surgery in Uterine Cancer
Int J Gynecol Cancer, 27 (4), 743-747
DOI 10.1097/IGC.0000000000000959, PubMed 28375931
MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk
BMC Cancer, 17 (1), 97
DOI 10.1186/s12885-017-3094-y, PubMed 28158999
TGFβ splicing and canonical pathway activation in high-grade serous carcinoma
Virchows Arch, 470 (6), 665-678
DOI 10.1007/s00428-017-2127-x, PubMed 28432432
Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas
Am J Surg Pathol, 41 (9), 1231-1237
DOI 10.1097/PAS.0000000000000894, PubMed 28622181
Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy
Acta Obstet Gynecol Scand, 96 (5), 547-555
DOI 10.1111/aogs.13120, PubMed 28236297
[Properties of cancer cell DNA affects the prognosis]
Tidsskr Nor Laegeforen, 137 (19)
DOI 10.4045/tidsskr.16.0966, PubMed 29043733
Characteristics of tumor cell DNA affect prognosis
Tidsskr. Nor. Laegeforen., 137 (19), 1519-1523
C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease
PLoS One, 12 (7), e0182030
DOI 10.1371/journal.pone.0182030, PubMed 28759630
Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)
Br J Cancer, 116 (4), 455-463
DOI 10.1038/bjc.2016.435, PubMed 28118323
Enhanced Recovery After Surgery for Advanced Ovarian Cancer: A Systematic Review of Interventions Trialed
Int J Gynecol Cancer, 27 (6), 1274-1282
DOI 10.1097/IGC.0000000000000981, PubMed 28498237
Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial
Int J Gynecol Cancer, 27 (5), 1046-1050
DOI 10.1097/IGC.0000000000000982, PubMed 28525497
Pretreatment late-phase DCE-MRI predicts outcome in locally advanced cervix cancer
Acta Oncol, 56 (5), 675-681
DOI 10.1080/0284186X.2017.1294762, PubMed 28447564
Vulvar carcinoma in Norway: A 50-year perspective on trends in incidence, treatment and survival
Gynecol Oncol, 145 (3), 543-548
DOI 10.1016/j.ygyno.2017.03.008, PubMed 28356187
Patterns of Lymph Node Metastases in Apparent Stage I Low-Grade Epithelial Ovarian Cancer: A Multicenter Study
Ann Surg Oncol, 24 (9), 2720-2726
DOI 10.1245/s10434-017-5919-y, PubMed 28608122
Rare ovarian tumours: Epidemiology, treatment challenges in and outside a network setting
Eur J Surg Oncol, 45 (1), 67-74
DOI 10.1016/j.ejso.2017.09.025, PubMed 29108961
Long-term ototoxicity in women after cisplatin treatment for ovarian germ cell cancer
Gynecol Oncol, 145 (1), 148-153
DOI 10.1016/j.ygyno.2017.02.006, PubMed 28202195
Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
APMIS, 125 (9), 781-786
DOI 10.1111/apm.12715, PubMed 28585395
A study of chronic fatigue in Norwegian cervical cancer survivors
Gynecol Oncol, 146 (3), 630-635
DOI 10.1016/j.ygyno.2017.05.028, PubMed 28552254
A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway
Acta Obstet Gynecol Scand, 96 (10), 1162-1169
DOI 10.1111/aogs.13199, PubMed 28795770
The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study
Neuro Oncol, 19 (7), 976-985
DOI 10.1093/neuonc/now272, PubMed 28040713
Overweight, obesity and height as risk factors for meningioma, glioma, pituitary adenoma and nerve sheath tumor: a large population-based prospective cohort study
Acta Oncol, 56 (10), 1302-1309
DOI 10.1080/0284186X.2017.1330554, PubMed 28548875
A Call for New Communication Channels for Gynecological Oncology Trainees: A Survey on Social Media Use and Educational Needs by the European Network of Young Gynecological Oncologists
Int J Gynecol Cancer, 27 (3), 620-626
DOI 10.1097/IGC.0000000000000917, PubMed 28187096